Targeting the BNIP3-mediated mitophagy has been found to be combined with anti-CD30 antibody to improve the prognosis of CD30+ EBV + diffuse large B-cell lymphoma patients (Wang et al., 2024). This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.